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In late December 2019, reports from China of the inci-
dence of pneumonia with unknown etiology were sent 
to the World Health Organization (WHO). Shortly after-
wards, the cause of this disease was identified as the novel 
beta-coronavirus, SARS-CoV-2, and its genetic sequence 
was published on January 12, 2020. Human-to-human 
transmission via respiratory droplets and contact with 
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n INTRODUCTION
Coronavirus includes of a large family of vi-ruses that are common to both humans and 
animals (cattle, camels, cats and bats). Sometimes 
animal coronaviruses can infect humans, such as 
SARS-CoV, MERS-CoV, and now SARS-CoV-2. 
Acute respiratory tract infection due to SARS-
CoV-2 is currently spreading rapidly worldwide 
and has become a public health concern. This 
infection is now officially called the novel coro-
navirus disease (COVID-19) [1, 2]. COVID-19 is 
characterized by high fever, difficul breathing, 
dry cough and atypical pneumonia and is usually 
Le Infezioni in Medicina, n. 2, 185-191, 2020
confirmed by positive RNA test or computed to-
mography (CT) of lung [3]. COVID-19 is spread-
ing rapidly in the world and on 11 March 2020, 
WHO announced the outbreak a global pandemic 
[4, 5]. There are currently few studies on the path-
ogenic properties of SARS-CoV-2 and its spread-
ing mechanism, and the present knowledge is 
largely based on the characteristics of similar 
coronaviruses. The genomic similarities of SARS-
CoV-2 to SARS-CoV, which is known to cause a 
major outbreak of Severe Acute Respiratory Syn-
drome (SARS) with 8098 cases, 774 deaths and 
a final mortality rate of 9% in 2002-2003, can ex-
plain the structural and pathogenic features of the 
SARS-CoV-2 [6, 7]. The strategy of isolating cases 
and contacts in the fight against SARS-COV-2 has 
been implemented from the beginning, but it has 
had a different effect on different countries. After 
the first major outbreak in Wuhan, China in Jan-
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uary, South Korea, Iran and Italy in late February 
and early March 2020 became involved in this 
epidemic [8]. Many countries are currently com-
bating COVID-19 and trying to prevent its further 
spread and to reduce morbidity and mortality 
rates, and thereby to diminish the overall stress 
and tention in their health-care system [9]. Since 
there is no definitive cure and specific vaccine for 
SARS-CoV-2, all measures to supplying public 
health rely on preventing the spread of the virus 
by droplets and close contact and contaminated 
surfaces [1]. The person-to-person transmission 
and spreading from dry surfaces contaminated 
with nose, mouth and eyes secretions of infected 
person has been proven about SARS-CoV-2 [10, 
11]. Given the severity of this major outbreak and 
the importance of prevention and protectection 
against the spread of SARS-CoV-2, we summarize 
and review the latest findings by scientists about 
the SARS-CoV-2 persistence outside the body and 
strategies to prevent further its spread.
n PERSISTENCE SARS-COV-2 IN AIR 
The transmission of pathogens through aerosols 
have been proven in closed spaces. There are sev-
eral respiratory diseases that spread through air-
borne route, such as tuberculosis [12]. Based on 
the results of a retrospective cohort study after the 
2003 SARS epidemic, airborne transmission could 
play a significant role in the spread of disease 
[13]. SARS-CoV-2 can be released when coughing, 
talking and sneezing of infected person. Droplets 
containing the virus can infect others if they do 
not follow the safe distance [14]. Moriyama et 
al. have stated that low humidity and tempera-
tures increase the viability of SARS-CoV-2 in the 
droplets, and since the receptor of this virus, an-
giotensin converting enzyme II (ACE2), appears 
in a small number of type II alveolar cells, SARS-
CoV-2 defects ciliary clearance and defense innate 
immunity for greater access to deep lung tissue 
[15, 16]. According to a recent study published in 
the The New England Journal of Medicine, SARS-
CoV-2 can persist for 3 hours in aerosols [17]. 
Given this finding, safety considerations in the in-
fected sectors and ICU where infected patients are 
under surveillance are important to prevent the 
spread of contamination by aerosols. One of these 
is to prevent high traffic in the infected sections 
and to inhibition the virus spreading through the 
airflow. Careful regulation and inspection of air 
conditioning systems is very important, as air con-
ditioning in polluted areas must be done under 
negative pressure (Figure 1). A negative pressure 
room uses lower air pressure to allow outside air 
into the segregated environment. This traps and 
keeps potentially harmful particles within the 
negative pressure room by inhibition of internal 
air from leaving the space [18]. A study in Chi-
Figure 1 - Airflow movement in 
infected Room.
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na showed that negative pressure ventilation and 
high air exchange levels within CCU, ICU and 
ward room of Renmin Hospital were effective in 
reducing SARS-CoV-2 airborne [14]. To reduce the 
risk of airborne contamination, early detection of 
asymptomatic carriers for treatment or quaran-
tine, avoiding crowded communities, use of face 
masks in places where pollution is high, such as 
in hospitals and also when using public transpor-
tation equipment is recommended [14].
n SARS-COV-2 ON THE SURFACES
SARS-CoV-2 spreads mostly through respiratory 
droplets and then through contaminated surfac-
es. Recent studies have shown that SARS-CoV-2 
can persist on a variety of surfaces from hours to 
days (Figure 2) [17, 19]. Kampf and his colleagues 
stated that human coronaviruses can persist for 
up to 9 days at room temperature. This time can 
be up to 28 days for veterinary coronviruses, and 
the interesting thing is that with increasing the 
temperature to 30 degrees or more, coronavirus 
persistence was shorter [19]. This indicates that 
the person may get the virus and become infect-
ed after touching the infected objects. Although 
the load of SARS-CoV-2 on inanimate surfaces at 
the time of its outbreak is unclear, it does appear 
that can reduce the load of viruses on the surfaces 
by disinfectants, especially the surfaces touched 
by the patient and the space around the patient 
where have the highest viral load. WHO recom-
mends to ensure that disinfection and environ-
mental cleaning procedures are performed cor-
rectly and consistently. Environmental surfaces 
must be thoroughly cleaned with water and disin-
fectant. Using hospital disinfectants such as sodi-
um hypochlorite can be an effective method [20]. 
Disinfection and cleaning of frequently touched 
surfaces such as doors, toilets, desks, switches 
and sinks should be carried out with household 
disinfectants. Different types of biocidal agents 
such as alcohols, hydrogen peroxide, benzalko-
nium or sodium hypochlorite chloride are ap-
plied worldwide for disinfection [19]. It has been 
proven that disinfectants with 62-71% ethanol or 
0.1% sodium hypochlorite can reduce coronavi-
rus contamination on surfaces within one minute 
of exposure [19]. Cleaning should be done after 
disinfection for contaminated surfaces. Examples 
Figure 2 - Persistence of SARS-COV-2 on surfaces [19].
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of disinfectants and necessary duration for their 
effect on SARScoronavirus are shown in Table 1.
n PREVENTION OF SPREADING  
SARS-COV-2
Lifestyle (quality sleep, eating healthy and exer-
cise) and health observance play a major role in 
controlling and preventing the virus spreading 
(Figure3) [25, 26]. According to CDC recommen-
dations, the main strategies for preventing the 
spread of the virus include:
 – Avoiding contact with symptomatic persons.
 – Covering sneeze or cough with a tissue and 
discarding the contaminated tissue in a con-
tained trash.
 – Avoiding travel to high risk areas.
 –  Wash hands with soap and water for at least 
20 seconds.
 – If soap was unavailable, use a disinfectant that 
contains at least 60% alcohol.
 – Avoiding hand contact with facial components
 – Cleaning and disinfecting repeatedly touched 
surfaces [27].
Table 1 - Inactivation of SARS coronavirus Strain FFM1 by different types of biocidal agents.
Virus Biocidal agent Reduction of viral infectivity (log10) Exposure time Ref
SARS coronavirus
Strain FFM1
Ethanol 95%
Ethanol 78%
2-Propanol 75%
2-Propanol 70%
Formaldehyde 1%
Glutardialdehyde 0.5%
Povidone iodine 0.23%
≥ 5.5
≥ 5.0
≥ 4.0
≥ 3.3
>3.0
>3.0
≥4.4
30s
30s
30s
30s
2min
2min
15s
[21]
[21]
[22]
[23]
[23]
[23]
[24]
Figure 3 - Preventive and protective measures against COVID-19
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n PERFORMANCE OF FACE MASKS  
AGAINST SARS-COV-2
The size of the coronavirus-shaped spherical par-
ticles is estimated to be about 0.125 microns (125 
nm) using an electron microscope. The smallest of 
them are 0.06 microns and the largest are 0.14 mi-
crons [3]. The most common masks used by health 
care workers and the general public include:
Surgical mask: 
Surgical masks are generally created to protect 
vulnerable patients from doctors and health care 
professionals can protect the wearer against large 
droplets and sprays [28]. Although these masks 
have been widely used by the public, there is no 
evidence that these masks are protective against 
SARS-CoV-2, but may slightly reduce the spread 
of the virus from the infected patient [29].
N95 respirator
An N95 mask is a type of respirator which filter 
out at least 95% of very small particles (0.3 mi-
cron). N95 masks should be used in health care 
center where health-care workers are in straight 
contact with patient [30]. Although experience 
has shown that these masks are used continuous-
ly or intermittently for 8 hours, they are usually 
used at health centers by health concerns (such 
as loss of performance due to contamination) or 
practical considerations (e.g., the need to Resting 
or using the toilet) is indicated [31].
FFP2 respirator
A filtering face piece 2 (FFP2) respirator out at least 
94% of very small particles (0.3 micron). FFP2 or N95 
are the gold standard to protection against very small 
particles [32, 33]. Figure 4 shows the types of masks 
based on the filter capacity, the ability to capture par-
ticles with a diameter of 0.3 microns or larger.
n IS THE MASK NECESSARY  
FOR EVERYONE OR NOT?
Despite the consensus that there is a need to use 
masks in symptomatic patients and staff in med-
Figure 4 - Types of face masks (removing power of 0.3 micron particle)
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ical centers, disagreements have been observed 
for the general population [34]. According to 
health recommendations in Germany and the 
UK, evidence supporting the effective protective 
effect of face masks for members in the commu-
nity is extremely rare. However, the use of the 
mask as a precautionary measure when caring 
for patients with respiratory infections is on the 
agenda of health-care workers [35]. It is wise for 
vulnerable people to avoid crowded areas and 
use surgical masks when exposing in high risk 
regions [36]. Currently, WHO recommend using 
the mask only to people with respiratory symp-
toms and to healthy people who are caring for 
someone with respiratory symptoms [37]. How-
ever, given the recent findings by scientists that 
the virus survives in the air for 3 hours [17], it 
is necessary to discuss the need to use the face 
masks for people in the community in addition 
to the medical staff.
n CONCLUSION
COVID-19 is now a global health threat and the 
number of confirmed reports of new cases and 
deaths is increasing every day. Since the SARS-
CoV-2 can remain in the air and on surfaces for 
several hours to several days, in addition to ob-
serving individual hygiene tips such as regular 
hand washing and avoiding contact, use of nega-
tive pressure ventilation in hospital sectors, open 
space, the face mask wearing in the crowded 
areas, disinfection of frequently touched surfac-
es is required to reduce SARS-CoV-2 spreading 
through of aerosol. however, it is clear that hand 
hygiene compliance and isolation or quarantine 
alone cannot prevent the spread of SARS-CoV-2. 
Therefore, further research needs to be done to in-
crease knowledge about the structural and patho-
genic features of SARS-CoV-2 and to find effective 
therapies and vaccines to control this disease.
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